Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – Still a Buy?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s stock price gapped up before the market opened on Thursday . The stock had previously closed at $26.40, but opened at $28.3630. Chugai Pharmaceutical shares last traded at $27.17, with a volume of 7,508 shares traded.

Chugai Pharmaceutical Stock Performance

The company has a market capitalization of $89.12 billion, a price-to-earnings ratio of 33.85 and a beta of 0.63. The business’s 50-day simple moving average is $24.24 and its 200-day simple moving average is $24.07.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings results on Friday, October 24th. The company reported $0.23 earnings per share for the quarter. Chugai Pharmaceutical had a net margin of 32.74% and a return on equity of 20.63%. The business had revenue of $2.26 billion during the quarter. On average, analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.